Gain Therapeutics (GANX) Cash from Operations (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Cash from Operations of 4727527.0 for Q1 2026, down 23.71% year-over-year from 6196605.99 in Q1 2025, and down 2.36% quarter-over-quarter from 4618487.0 in Q4 2025.
Gain Therapeutics (GANX) Cash from Operations (2020 - 2026) Analysis & Trends
Gain Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 4727527.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 23.71% year-over-year to 4727527.0; the TTM figure through Mar 2026 stood at 19371432.0 (down 1.37% YoY), while the FY2025 annual figure was 18465432.0, up 2.16% from the prior year.
- Cash from Operations for Q1 2026 stood at 4727527.0, down from 4618487.0 in the prior quarter.
- The five-year high for Cash from Operations was 2447391.0 in Q1 2022, with the low at 6076205.0 in Q3 2024.
- The 5-year median for Cash from Operations is 4618487.0 (2025), against an average of 4448517.53.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations tumbled 72.32% in 2023, then surged 38.97% in 2024.
- Gain Therapeutics' Cash from Operations stood at 3904613.0 in 2022, then sank by 44.97% to 5660379.0 in 2023, then soared by 38.97% to 3454636.0 in 2024, then slumped by 33.69% to 4618487.0 in 2025, then dropped by 2.36% to 4727527.0 in 2026.
- Business Quant data shows GANX's Cash from Operations at 4727527.0 in Q1 2026, 4618487.0 in Q4 2025, and 4926436.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - | -4.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.68 Mn |
| Jun 30, 2026 | -4.68 Mn |
| Mar 31, 2026 | -4.73 Mn |
| Mar 31, 2026 | -4.73 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Dec 31, 2025 | -4.62 Mn |
| Sep 30, 2025 | -4.93 Mn |
| Sep 30, 2025 | -4.93 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | -5.10 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Mar 31, 2025 | -3.82 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | -6.08 Mn |
| Sep 30, 2024 | -6.08 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Jun 30, 2024 | -5.76 Mn |
| Mar 31, 2024 | -3.59 Mn |
| Mar 31, 2024 | -3.59 Mn |